Dengue Clinical Trial
Official title:
Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis
Dengue is the most common viral illness spread by mosquitos. It is important to diagnose dengue to prompt adequate therapy and initiate local mosquito control. Easy to use point of care tests are needed to improve dengue diagnosis. Oral fluid collection may be a simple, non-invasive way to diagnose dengue in the community. However, it is currently unknown if oral fluid is an accurate way to diagnose dengue and if the use of a specialized oral fluid collector could help to improve dengue diagnosis. In this study, the investigators will analyze the oral fluid of suspected dengue patients compared to serum samples for dengue diagnosis. From this information the investigators will be able to determine if oral fluid is a convenient way to diagnose dengue and if the oral fluid collector aids in improving diagnosis.
Dengue continues to spread and threaten approximately 3.6 billion people. It is crucial to
adequately recognize dengue and start early intervention. Dengue virus (DENV) infections are
typically confirmed by virus isolation and nucleic acid detection, both of which require
trained personnel and advanced facilities that are limited in developing countries. Detection
of antibodies serves as a viable and cheaper diagnostic alternative, and one method of doing
so is through oral fluid. Detecting DENV antibodies in oral fluid has been accomplished. The
utility of oral fluids is attractive as specimens can be acquired in a faster, non-invasive
manner that is suitable for children and needle-phobic adults. One challenge of using oral
fluid for dengue diagnosis is that typically, oral fluid contains the same analytes found in
blood, albeit in lower concentrations, thus there is a need for protein concentration if oral
fluid will be used for diagnosis.
A device capable of collecting oral fluid is the Sani-Sal® oral fluid collector, used
successfully in rapid diagnostics of HIV. It is a unique device that claims to concentrate
oral fluid proteins, decrease oral fluid viscosity, and stimulate salivation. These
properties make the Sani-Sal® potentially valuable in the diagnosis of DENV in the field by
concentrating antibodies to identify early infection.
Furthermore, dengue is commonly misdiagnosed or undiagnosed given varying clinical
manifestations, lack of patient health seeking behavior, and lack of incentives for
physicians to confirm and report cases. Knowledge on the health-seeking behaviors of dengue
patients remains limited. The project will also assess patient and practitioner perceptions
regarding dengue diagnostics, care, and reporting while considering the utility of this novel
diagnostic technology. Lastly, the study will seek to understand the role of governance in
communicable disease surveillance, reporting and information flow.
This application seeks approval to pilot a study which will seek to determine whether the
SaniSal® can be useful in DENV diagnosis by concentrating DENV IgM antibodies and NS1
antigens. The study will also like to explore the knowledge, attitude, practices and health
seeking behaviors of patients, while understanding dengue training, diagnosis and reporting
amongst practitioners. The study will be conducted in partnership with the Instituto Nacional
de Diabetes (INDEN) and Dr. Roberto Reid Cabral's Children's Hospital in Santo Domingo,
Dominican Republic—where dengue is endemic.
The utility of oral-fluid in diagnostics is promising: it can serve as efficient tools for
point-of-care practices and as an alternative to blood-draw. If this study shows that saliva
can be equally effective in the detection of DENV as blood on an ELISA confirmatory test,
then the investigators can mitigate the limitations of serum testing. This can result in
increased rapid diagnostic confirmation of suspected cases, improving on patient comfort and
care while assisting in targeted vector control. This coupled with insights on policies,
perceptions and behaviors surrounding DENV can help improve point-of-care diagnostics,
reporting and surveillance, and community education efforts during epidemics in endemic
countries of the Caribbean region.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
Recruiting |
NCT04582474 -
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
|
N/A | |
Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
Completed |
NCT03803618 -
Dengue Effectiveness Study in the Philippines
|
||
Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 |